Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Change in Account Payables (2016 - 2025)

Altimmune (ALT) has disclosed Change in Account Payables for 16 consecutive years, with $4.0 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Account Payables rose 354.21% to $4.0 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.7 million, a 291.9% increase, with the full-year FY2024 number at -$1.9 million, up 32.0% from a year prior.
  • Change in Account Payables was $4.0 million for Q3 2025 at Altimmune, up from -$226000.0 in the prior quarter.
  • In the past five years, Change in Account Payables ranged from a high of $4.0 million in Q3 2025 to a low of -$1.6 million in Q3 2024.
  • A 5-year average of $220631.6 and a median of -$194000.0 in 2021 define the central range for Change in Account Payables.
  • Biggest YoY gain for Change in Account Payables was 872.3% in 2021; the steepest drop was 308.19% in 2021.
  • Altimmune's Change in Account Payables stood at $2.0 million in 2021, then surged by 66.91% to $3.4 million in 2022, then tumbled by 128.83% to -$976000.0 in 2023, then increased by 5.53% to -$922000.0 in 2024, then surged by 528.74% to $4.0 million in 2025.
  • Per Business Quant, the three most recent readings for ALT's Change in Account Payables are $4.0 million (Q3 2025), -$226000.0 (Q2 2025), and $866000.0 (Q1 2025).